These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11673691)

  • 21. [Inhibitory effect of bcl-2 antisense oligodeoxynucleotides on growth of human lung carcinoma xenograft in nude mice].
    He DM; Zhang H
    Ai Zheng; 2006 Jan; 25(1):40-4. PubMed ID: 16405747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line.
    Yasuoka Y; Naomoto Y; Yamatsuji T; Takaoka M; Kimura M; Uetsuka H; Matsubara N; Fujiwara T; Gunduz M; Tanaka N; Haisa M
    Exp Cell Res; 2001 Dec; 271(2):214-22. PubMed ID: 11716533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
    Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
    Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
    Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
    Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotides in lung cancer.
    Pujol JL; Jacot W
    Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract]   [Full Text] [Related]  

  • 28. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis.
    Song HF; Tang ZM; Yuan SJ; Zhu BZ
    Acta Pharmacol Sin; 2000 Jan; 21(1):80-6. PubMed ID: 11263253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.
    Advani PP; Paulus A; Masood A; Sher T; Chanan-Khan A
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):765-74. PubMed ID: 21521129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
    Holmlund JT
    Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer.
    Kikuchi E; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    J Urol; 2003 Feb; 169(2):730-4. PubMed ID: 12544353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A
    Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
    [No Abstract]   [Full Text] [Related]  

  • 38. Bcl-2-related antisense therapy.
    Gutiérrez-Puente Y; Zapata-Benavides P; Tari AM; López-Berestein G
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):71-6. PubMed ID: 12138400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
    Schumacher C; Cioffi CL; Sharif H; Haston W; Monia BP; Wennogle L
    Mol Pharmacol; 1998 Jan; 53(1):97-104. PubMed ID: 9443936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
    Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
    J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.